Merck to acquire HUB Organoids to advance cell culture portfolio
Acquisition to advance company's next generation biology portfolio with internationally recognized pioneer in organoid development
Acquisition to advance company's next generation biology portfolio with internationally recognized pioneer in organoid development
The TGA approval marks a pivotal step in Rusan Pharma’s expansion into the Australian market
Till 30th November 2024, more than 2690 PACS have been given initial approval and 687 Kendras have been opened in PACS
Harnessing advanced data analysis for early detection, prevention and better outcomes
The trademark rights for these brands will be transferred to Lupin by March next year.
Zefylti will be available as 30 MU/0.5 mL and 48 MU/0.5 mL and is intended for the treatment of neutropenia and the mobilisation of peripheral progenitor cells
The CDMO business will be structured into three new business platforms designed to create a unified organization: Integrated Biologics, Advanced Synthesis, and Specialized Modalities
Brenntag Specialties Pharma marks a strategic milestone with its first collaboration with a contract manufacturer to enhance its nutraceutical value chain
The fixed-dose combination of Abacavir 60 mg/Dolutegravir 5 mg/Lamivudine 30 mg tablets for oral suspension is a once-daily single-pill regimen
Subscribe To Our Newsletter & Stay Updated